Tc-99m Methylene Diphosphonate Bone Scintigraphy Research Articles

Malignancy incidence and primary tumor investigation in the patients with vertebral compression fractures by means of combined Tc-99m methylene diphosphonate bone scintigraphy and fluorodeoxyglucose positron emission tomography/computed tomography

Purpose: Vertebral compression fractures frequently present with back pain and are determined by magnetic resonance (MR) imaging. However, fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) is performed to determine the pathological fractures and primary tumors in a single imaging modality. The aim of this study is to evaluate the incidence of pathological fractures and primary tumors by means of combined bone scintigraphy and FDG PET/CT. Materials and Methods: Twenty-eight patients (15 females, 13 males; mean: 67.8 ± 11.6 years) with compression fractures determined by MR or plain radiographs were the subject of this study. The patients were referred for whole-body bone scintigraphy and due to the suspicion of metastasis additional FDG PET/CT was performed. The results of both studies were compared with the pathological and/or follow-up results. Results: The bone scintigraphy and PET/CT did not reveal concordant results according to the Kappa test. The SUVmax cutoff value was accepted as “7” and with this cutoff value, PET/CT achieved 57.1% sensitivity and 95.2% specificity in the determination of pathologic compression fractures. Conclusion: Although the results of bone scintigraphy and FDG PET/CT were not correlated with each other, FDG PET/CT revealed high specificity in the detection of pathologic fractures.

Clinical Use of Quantitative Analysis of Bone Scintigraphy to Assess the Involvement of Arthritis Diseases in Patients with Joint Symptoms.

We aimed to compare the diagnostic ability of quantitative analysis of bone scintigraphy with that of visual analysis for identifying arthritis disease involvement in patients with joint symptoms. We retrospectively included 93 patients with joint symptoms who underwent Tc-99m methylene diphosphonate bone scintigraphy for evaluating arthritis disease involvement. Bone scintigraphy images were visually and quantitatively analyzed using an in-house software by two reviewers. On quantitative analysis, joint uptake ratio was measured for 64 joints in 14 joints areas. The inter-rater agreement of visual and quantitative analyses was assessed, and diagnostic abilities were compared based on the area under the receiver operating characteristic (ROC) curve (AUC) values. Regarding visual analysis, there was a moderate degree of inter-rater agreement (kappa coefficient of 0.597), while there was a substantial inter-rater agreement (concordance correlation coefficient of 0.987) in the measurement of the joint uptake ratio. The comparisons of ROC curves for the total 5941 joints revealed that the joint uptake ratio had a significantly higher AUC value (0.789) to detect the affected joint than that of the visual analysis (p < 0.001). Quantitative analysis using joint uptake ratio showed substantial reproducibility and higher diagnostic ability to detect joints involving arthritis diseases than visual analysis on bone scintigraphy.

Super Scan Caused by Parathyroid Carcinoma Observed Both in 18F-FDG PET/CT Scan and Tc-99m MDP Bone Scintigraphy

Super scan is a well-known finding described in skeletal scintigraphy characterized by uniform symmetrically increased radiopharmaceutical uptake by bones and consequently diminished renal parenchymal activity. Sy et al. hypothesized that the faint visualization of renal cortex in bone scintigraphy might be the result of increased uptake of radiopharmaceutical by pathologic bones and reduced phosphate excretion. The super scan on 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) has been observed in various conditions such as prostate cancer, lung cancer, renal adenocarcinoma, gastric cancer and primitive neuroectodermal tumor of the kidney. Herein we report the first case of super scan in a 68-year-old-woman with parathyroid carcinoma observed both in 18F-FDG PET/CT and Tc-99m methylene diphosphonate bone scintigraphy. There were extensive hypermetabolic lesions throughout the skeleton in 18F-FDG PET/CT. In contrast to the intense hypermetabolism of the skeleton; the liver, skeletal muscles of the limbs, mediastinum, bowel and especially the brain showed very low FDG uptake. Additionally, there was increased skeletal radiotracer uptake relative to soft tissue, and faint genitourinary tract activity in bone scintigraphy.

Diagnosis and semiquantification of osteonecrosis of the jaw by bone scan index on bone scintigraphy.

e639 Background: Bone management is extremely important for maintaining QOL of prostate or renal cancer patients with bone metastasis. Physicians often administrate bone modifying agents (BMA), zoledronic acid or denosumab, to prevent skeletal-related event and bone pain for such patients. However, osteonecrosis of the jaw (ONJ) is one of sever adverse events of BMA (Medication-related ONJ; MRONJ). The early detection and follow-up of ONJ is extremely important issue. In order to achieve this issue, we utilized bone scintigraphy and a computer-aided diagnosis using a bone scan index (BSI). Methods: A total of 22 patients with either prostate cancer or renal cancer (27 lesions) diagnosed with MRONJ after treatment with BMA were investigated. Median age was 72.5 years (range 52-82 years). The primary disease was prostate cancer (81.8%), renal cancer (18.2%). Regarding the treatment, 86.4% of the patients were treated with bisphosphonate drugs, none in denosumab, and both in 13.6%, respectively. The median duration of medication was 33 months (range 7-70 months) by the time of MRONJ diagnosis. All patients underwent Tc-99m methylene diphosphonate bone scintigraphy. Bone uptake in the jaw was analyzed using BSI, which was calculated by BONENAVI (FUJIFILM RI Pharma, Japan; EXINIbone, EXINI Diagnostics, Sweden). Significant hot spots were manually selected according to both serial scintigraphic images and dental records, and the fraction of them to the entire skeleton was referred as BSI of the jaw (BSIJ). The level of BSIJ was evaluated in comparison with stage of ONJ and inflammation marker, C-reactive protein (CRP). Results: The median BSIJ of lesions was 0.14 (range 0.00-0.43) at the time of MRONJ diagnosis. If MRONJ is not treated appropriately, BSIJ tended to increase during treatment with BMA. When patients were classified according to their clinical stages of MRONJ, higher stage MRONJ lesions had significantly higher BSIJ (p &lt; 0.01). In addition, BSIJ was correlated with CRP. Conclusions: Evaluation of BSIJ using BONENAVI on bone scintigraphy was helpful for early detection and follow-up of MRONJ. Furthermore, increased BSIJ on bone scintigraphy were related to CRP and stage of ONJ.

Tc-99m MDP Uptake in a Giant Pulmonary Chondroma

Abstract: Pulmonary chondromas are very rare benign tumors. We report a case of huge solitary pulmonary chondroma in a 53-year-old woman without specific symptom. The lesion was detected by CT and Tc-99m methylene diphosphonate bone scintigraphy. The primary diagnosis after radiologic examination was pulmonary hamartoma. Then, surgical excision was performed, and the pathology showed pulmonary chondroma.

Tc-99m Methylene Diphosphonate Uptake by Numerous Phleboliths in the Lower Extremity Detected Incidentally During Bone Scintigraphy

Phleboliths are calcified thrombi within veins and very common in the veins of the lower part of the pelvis. Most adults have a small number of phleboliths. However, despite the high prevalence, phleboliths with increased uptake on bone scintigraphy have very rarely been reported in the literature. Tc-99m methylene diphosphonate bone scintigraphy was performed on a 46-year-old man with an abscess on the plantar surface of the left foot, which demonstrated incidental, irregular, mottled, increased uptake in the soft tissues of the left thigh and leg, which corresponded to numerous phleboliths on plain radiographs and CT.

Intense Accumulation of Tc-99m MDP in Pericardial Metastasis From Breast Cancer

Extraosseous uptake often seen on Tc-99m methylene diphosphonate bone scintigraphy has clinical significance. In a routine follow-up study on a 54-year-old female patient with breast cancer, we encountered a rare finding of pericardial metastasis clearly demonstrated by Tc-99m methylene diphosphonate bone scintigraphy. This incidental finding of increased uptake in the periphery of the cardiac contour on a bone scan reflects radionuclide accumulation in pericardium, myocardium, or pericardial effusion itself. In our case, an additional computed tomography examination of the chest was useful for making the definitive diagnosis of dystrophic calcification of the pericardium.

Dural Metastasis Demonstrated on Tc-99m MDP Bone Scintigraphy in Staging Workup for a Patient With Breast Cancer

An 80-year-old woman with multifocal invasive lobular carcinoma of the right breast treated 6 years previously with mastectomy, locoregional radiotherapy, and tamoxifen was referred for a bone scan to investigate generalized arthralgias. The patient reported right-sided headaches, blurred vision, and dizziness in the previous 3 months. The bone scan revealed a large area of unusual and abnormal Tc-99m methylene diphosphonate (MDP) uptake in the right frontoparietal skull region. CT and MRI of the brain were performed to evaluate the possibility of cerebral metastases. The CT revealed extensive abnormal thickening and enhancement of the dura in the right frontoparietal region. No calcification of the dura or bony destruction of the overlying skull was evident on CT. MRI similarly revealed extensive thickening and irregularity of the dura. The usual causes of increased skull Tc-99m MDP uptake on bone scanning such as skull metastases and dural calcification were not evident on CT or MRI.

Tc-99m MDP bone scintigraphy of myositis as a manifestation of chronic graft-versus-host disease after non-myeloablative peripheral stem cell transplantation

A 27-year-old man developed polymyositis as a manifestation of chronic graft-versus-host disease (GVHD) after non-myeloablative peripheral blood stem cell transplantation (PBSCT). Bone scintigraphy showed intense, striped, and heterogeneous accumulation of Tc-99m methylene diphosphonate (MDP) in the soft-tissue of his lower limbs, while faint activities were seen in the right upper limb. Tc-99m MDP scintigraphy was very useful for accurate and objective evaluation of the severity of the muscle injury and the extent of polymyositis caused by chronic GVHD.

Re-186 HEDP Conditioning Therapy in Patients With Advanced Acute Lymphoblastic Leukemia Before Allogeneic Bone Marrow Transplantation

The authors present their experience with dose calculation of Retin1,1-hydroxyethylidene-186-diphosphonate (Re-186 HEDP) therapy used as part of an intensified conditioning regimen before allogeneic stem cell transplantation in 2 patients with advanced acute lymphoblastic leukemia during the second partial or third complete remission. Kidneys were shielded during total-body irradiation (TBI) to limit the TBI-mediated renal radiation dose to 7 Gy. The aim of this dose calculation of Re-186 HEDP therapy was to deliver additional radiotherapy to the red bone marrow without exposing more than an additional 5 Gy to the kidneys in addition to the TBI standard dose of 12.6 Gy. Pretherapeutic kidney scintigraphy (Tc-99m mercaptoacetyltriglycine) showed normal results. Thus, dynamic Tc-99m methylene diphosphonate bone scintigraphy was used to calculate the expected bone marrow and kidney doses. A total amount of 8.8 GBq (238 mCi) Re-186 HEDP was given to patient no. 1 and 14.3 GBq (387 mCi) Re-186 HEDP was given to patient no. 2. Re-186 HEDP activity was monitored based on its gamma radiation measurement daily for 5 days in patient no. 1 and 7 days in patient no. 2. Therapeutic Re-186 isotope distribution and biologic half-life correlated well with the prediction by a pretherapeutic Tc-99m methylene diphosphonate scan. The calculated effective Re-186 bone marrow dose was 3.3 Gy for patient no. 1 and 5.6 Gy for patient no. 2. Effective kidney doses were 1.6 Gy and 2.1 Gy respectively. No unexpected complications occurred after completing conditioning and allogeneic stem cell transplantation. Posttransplant kidney function remained normal. Patient no. 1 remains in a second complete remission of his advanced acute lymphoblastic leukemia 18 months after HEDP therapy. Patient no. 2 relapsed 5 months after transplantation and eventually died as a result of progressive disease. The authors conclude that Re-186 HEDP will be able to increase the total additional bone marrow dose. In patients in whom the kidney dose is limited to 5 Gy in addition to TBI, doses near 10 Gy can be achieved on the bone marrow.

FDG–PET for detection of recurrences from malignant primary bone tumors: comparison with conventional imaging

BackgroundThe aim of this study was to assess the diagnostic ability of positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-d-glucose (FDG–PET) in the detection of recurrences from malignant primary bone tumors compared with conventional imaging. Patients and methodsIn 27 patients (6 osteosarcomas, 21 Ewing’s sarcomas), 41 FDG–PET examinations performed for diagnosis or exclusion of recurrent disease were evaluated. Conventional imaging techniques consisted of magnetic resonance imaging of the primary tumor site, thoracic computed tomography, and Tc-99m methylene diphosphonate bone scintigraphy. The reference methods were the histopathological analysis and/or the clinical and imaging follow-up. ResultsIn 25 examinations reference methods revealed 52 sites of recurrent disease (local n = 7; distant: osseous n = 22, pulmonary n = 13, soft tissue n = 10). On an examination-based analysisFDG–PET had a sensitivity of 0.96, a specificity of 0.81 and an accuracy of 0.90. Corresponding values for conventional imaging were 1.0, 0.56 and 0.82. ConclusionsThe sensitivity, specificity and accuracy of FDG–PET in the detection of recurrences from osseous sarcomas are high. On an examination-based analysis, FDG–PET had a not significantly lower sensitivity in comparison with conventional imaging. However, FDG–PET showed a small advantage in the detection of osseous and soft-tissue recurrences compared with conventional imaging.

Technetium-99m MDP bone scintigraphic findings of hypercalcemia in accelerated phase of chronic myelogenous leukemia

Hypercalcemia in accelerated phase of chronic myelogenous leukemia (CML) is very rare. Its pathogenesis is considered humoral hypercalcemia of malignancies mediated by parathyroid hormone-related protein (PTHrP). In severe hypercalcemia, calcifications in kidneys, skin, vessels, heart, and stomach may occur. Our two cases were admitted because of severe hypercalcemia in accelerated phase of CML. On Tc-99m methylene diphosphonate (MDP) bone scintigraphies, a marked tracer accumulation was seen in the lung, heart, stomach and kidney. We report increased tracer accumulation of multiple organs on Tc-99m MDP bone scintigraphy in two rare hypercalcemic patients with CML.

Bone Metastases and Bone Pain in Breast Cancer

One hundred ninety patients with breast cancer were prospectively evaluated for bone pain and had technetium Tc 99m-methylene diphosphonate bone scintigraphy for bone metastases. Of the 66 patients showing evidence for bone metastases, 21 (32%) did not have bone pain. There were 155 sites of skeletal metastases, but pain was found only in 50 sites. The age of the patient or involvement of weight-bearing bones did not seem to affect the association between bone metastases and pain. We discuss the need for periodic bone scintigraphy, even when the clinical state does not seem to warrant it.